C4 Therapeutics (CCCC) 10-K2024 FY Annual report

Filed: 27 Feb 25, 7:15am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: BIOSECURE, Bright, brokerage, caption, cemsidomide, chair, citizen, CODM, Darmstadt, declaratory, deploy, disaster, Fawell, flat, fluid, Footnote, footprint, foundation, furlough, Germany, Hematology, Hoerter, intangible, Italy, KGaA, Koppikar, Kpuu, language, Loper, Mexico, MKDG, orthosteric, overturn, overturned, predominantly, presidential, psychological, punishable, Raimondo, reconciling, repriced, repricing, Ronald, rumored, scrutinizing, Spain, Stephen, Steve, Subtopic, tasked, TD, unrest, Utpal, water, weather

Removed: allograft, angioimmunoblastic, arm, artery, assay, BID, Bioluminescence, BLI, blot, bortezomib, BTK, chemoimmunotherapy, clearance, clinic, creation, cutoff, daily, delete, depicted, depth, diligent, DiscoveryX, dissolution, diverse, encode, enteropathy, enzymology, Epidemiology, exhibited, expanding, expression, Female, flexibility, formatted, forty, graph, hepatosplenic, hit, incorporating, induced, injection, Inline, inoculated, Interactive, intracarotid, intracranial, issuable, kinetic, Kinome, KINOMEscan, lieu, linking, locally, luciferase, meaningfully, mechanical, mice, modular, nanomolar, nM, nude, Optimizer, oriented, par, precision, preemptive, preferential, prioritize, profiling, proportional, quantify, quantitation, quantitative, ratably, redemption, regression, RET, rituximab, routinely, sandbox, screen, secured, SEER, silico, sinking, spectrometry, subscription, suppression, tailored, throughput, TKI, transformed, transitioning, utilizing, venetoclax, western, wild, winding, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CCCC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of C4 Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: February 27, 2025	By:	/s/ Kendra R. Adams
		Kendra R. Adams
		Chief Financial Officer
		(Principal financial officer)